Multi-modal molecular programs regulate melanoma cell state.


Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
09 07 2022
Historique:
received: 09 03 2021
accepted: 20 06 2022
entrez: 9 7 2022
pubmed: 10 7 2022
medline: 14 7 2022
Statut: epublish

Résumé

Melanoma cells display distinct intrinsic phenotypic states. Here, we seek to characterize the molecular regulation of these states using multi-omic analyses of whole exome, transcriptome, microRNA, long non-coding RNA and DNA methylation data together with reverse-phase protein array data on a panel of 68 highly annotated early passage melanoma cell lines. We demonstrate that clearly defined cancer cell intrinsic transcriptomic programs are maintained in melanoma cells ex vivo and remain highly conserved within melanoma tumors, are associated with distinct immune features within tumors, and differentially correlate with checkpoint inhibitor and adoptive T cell therapy efficacy. Through integrative analyses we demonstrate highly complex multi-omic regulation of melanoma cell intrinsic programs that provide key insights into the molecular maintenance of phenotypic states. These findings have implications for cancer biology and the identification of new therapeutic strategies. Further, these deeply characterized cell lines will serve as an invaluable resource for future research in the field.

Identifiants

pubmed: 35810190
doi: 10.1038/s41467-022-31510-1
pii: 10.1038/s41467-022-31510-1
pmc: PMC9271073
doi:

Substances chimiques

MicroRNAs 0
RNA, Long Noncoding 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

4000

Subventions

Organisme : NCI NIH HHS
ID : P50 CA221703
Pays : United States
Organisme : NCI NIH HHS
ID : R50 CA221675
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA093459
Pays : United States

Informations de copyright

© 2022. The Author(s).

Références

Nature. 2000 Aug 3;406(6795):536-40
pubmed: 10952317
Int J Mol Sci. 2019 Feb 13;20(4):
pubmed: 30781795
Nat Commun. 2015 Apr 09;6:6683
pubmed: 25865119
Science. 2016 Apr 8;352(6282):189-96
pubmed: 27124452
Genome Res. 2012 Oct;22(10):1995-2007
pubmed: 22637570
Bioinformatics. 2015 Jan 15;31(2):166-9
pubmed: 25260700
J Invest Dermatol. 2015 Feb;135(2):532-541
pubmed: 25243790
Bioinformatics. 2019 Jul 15;35(14):i436-i445
pubmed: 31510660
Ann Oncol. 2015 Jan;26(1):64-70
pubmed: 25319062
Cancer Cell. 2013 Oct 14;24(4):466-80
pubmed: 24075834
Bioinformatics. 2009 Jul 15;25(14):1754-60
pubmed: 19451168
EMBO Mol Med. 2017 Aug;9(8):1011-1029
pubmed: 28606996
Cell. 2017 Nov 2;171(4):934-949.e16
pubmed: 29033130
J Immunol. 2001 Jun 1;166(11):6483-90
pubmed: 11359798
Clin Chem. 2010 Jun;56(6):998-1006
pubmed: 20378769
Science. 2015 Oct 9;350(6257):207-211
pubmed: 26359337
Oncoimmunology. 2019 Oct 16;9(1):1659093
pubmed: 32002281
Cell. 2018 Nov 1;175(4):998-1013.e20
pubmed: 30388456
Bioinformatics. 2009 Oct 15;25(20):2625-31
pubmed: 19692556
Cancer Res. 2017 Nov 1;77(21):e108-e110
pubmed: 29092952
Nat Rev Cancer. 2019 Jul;19(7):377-391
pubmed: 31209265
Bioinformatics. 2016 Oct 1;32(19):3012-4
pubmed: 27288499
Nat Biotechnol. 2012 May;30(5):413-21
pubmed: 22544022
Proc Natl Acad Sci U S A. 2004 Mar 23;101(12):4164-9
pubmed: 15016911
Nat Commun. 2017 Oct 26;8(1):1136
pubmed: 29070816
Lab Invest. 2017 Jun;97(6):649-656
pubmed: 28263292
Nat Protoc. 2009;4(1):44-57
pubmed: 19131956
Nat Biotechnol. 2013 Mar;31(3):213-9
pubmed: 23396013
Nucleic Acids Res. 2015 Jan;43(Database issue):D146-52
pubmed: 25378301
N Engl J Med. 2010 Aug 19;363(8):711-23
pubmed: 20525992
Trends Cell Biol. 2019 Mar;29(3):212-226
pubmed: 30594349
Pigment Cell Melanoma Res. 2012 May;25(3):343-53
pubmed: 22336146
Nature. 2012 Oct 18;490(7420):412-6
pubmed: 23051752
Cancer Cell. 2017 Aug 14;32(2):204-220.e15
pubmed: 28810145
Nature. 2020 Jan;577(7791):556-560
pubmed: 31942077
Genome Med. 2019 May 24;11(1):34
pubmed: 31126321
Genome Res. 2010 Sep;20(9):1297-303
pubmed: 20644199
J Biomed Inform. 2011 Oct;44(5):839-47
pubmed: 21605702
Genome Biol. 2014;15(12):550
pubmed: 25516281
Cell. 2015 Jan 15;160(1-2):48-61
pubmed: 25594174
Mol Cell. 2010 Dec 10;40(5):841-9
pubmed: 21109473
Clin Cancer Res. 2014 Oct 1;20(19):5064-74
pubmed: 24714771
Methods Mol Biol. 2020;2120:233-248
pubmed: 32124324
Nat Commun. 2015 Dec 04;6:8971
pubmed: 26634437
Cancer Discov. 2014 Jul;4(7):816-27
pubmed: 24771846
Cancer Res. 2008 Feb 1;68(3):650-6
pubmed: 18245463
N Engl J Med. 2015 Jan 22;372(4):320-30
pubmed: 25399552
J Clin Invest. 2015 Apr;125(4):1459-70
pubmed: 25705882
Cell. 2016 Mar 24;165(1):35-44
pubmed: 26997480
Cancer Res. 2004 Jan 15;64(2):509-16
pubmed: 14744763
Science. 2017 Jan 20;355(6322):
pubmed: 28104840
Bioinformatics. 2015 Mar 15;31(6):912-8
pubmed: 25380958
Cancer Discov. 2016 Aug;6(8):827-37
pubmed: 27301722
Nucleic Acids Res. 2018 Jan 4;46(D1):D296-D302
pubmed: 29126174
Nucleic Acids Res. 2010 Sep;38(16):e164
pubmed: 20601685
N Engl J Med. 2018 Apr 05;378(14):1277-1290
pubmed: 29562145
N Engl J Med. 2015 Oct 22;373(17):1627-39
pubmed: 26412456
Cell. 2015 Jun 18;161(7):1681-96
pubmed: 26091043
J Invest Dermatol. 2014 Feb;134(2):441-451
pubmed: 23934065
Pigment Cell Melanoma Res. 2013 Jul;26(4):597-600
pubmed: 23527996
Bioinformatics. 2011 Oct 1;27(19):2648-54
pubmed: 21828086
Methods Mol Biol. 2014;1182:289-305
pubmed: 25055920
Nat Commun. 2014 Dec 15;5:5712
pubmed: 25502142
Nat Biotechnol. 2009 Feb;27(2):182-9
pubmed: 19182786
Am J Pathol. 2003 Jul;163(1):333-43
pubmed: 12819038
Genome Biol. 2016 Oct 20;17(1):218
pubmed: 27765066
Nat Cell Biol. 2020 Aug;22(8):986-998
pubmed: 32753671
Trends Immunol. 2002 Nov;23(11):549-55
pubmed: 12401408
Pigment Cell Melanoma Res. 2015 Jul;28(4):431-41
pubmed: 25903073
Clin Dev Immunol. 2012;2012:948098
pubmed: 22778768
Pigment Cell Melanoma Res. 2010 Apr;23(2):160-70
pubmed: 20128875
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
PLoS One. 2010 Nov 01;5(11):e13779
pubmed: 21072171
J Am Acad Dermatol. 2014 Aug;71(2):237-44
pubmed: 24906614
Cell. 1994 Dec 30;79(7):1267-76
pubmed: 8001159
JCO Precis Oncol. 2018;2018:
pubmed: 30094412
Science. 2018 Jan 5;359(6371):97-103
pubmed: 29097493
Science. 2015 Nov 27;350(6264):1084-9
pubmed: 26541606
Cancer Cell. 2018 May 14;33(5):890-904.e5
pubmed: 29657129
PLoS One. 2007 Nov 21;2(11):e1195
pubmed: 18030330
Nature. 2020 Jan;577(7791):561-565
pubmed: 31942071
Cell. 2015 Sep 10;162(6):1271-85
pubmed: 26359985
Nucleic Acids Res. 2009 Jan;37(1):1-13
pubmed: 19033363
Bioinformatics. 2013 Jan 1;29(1):15-21
pubmed: 23104886
Clin Proteomics. 2010 Dec;6(4):129-51
pubmed: 21691416
Cell. 2018 Aug 9;174(4):843-855.e19
pubmed: 30017245
Front Cell Dev Biol. 2018 Jun 12;6:56
pubmed: 29946544
BMC Med. 2016 Oct 25;14(1):168
pubmed: 27776519
Immunotherapy. 2016 Jun;8(6):733-46
pubmed: 27197541
Science. 2015 Nov 27;350(6264):1079-84
pubmed: 26541610
Pigment Cell Melanoma Res. 2016 May;29(3):266-83
pubmed: 26833684
Proc Natl Acad Sci U S A. 2017 Dec 26;114(52):13679-13684
pubmed: 29229836
Genome Biol. 2011;12(1):R1
pubmed: 21205303
Nature. 2005 Jul 7;436(7047):117-22
pubmed: 16001072
J Invest Dermatol. 2011 Dec;131(12):2448-57
pubmed: 21796150
Sci Transl Med. 2017 Mar 1;9(379):
pubmed: 28251903
Epigenetics. 2015;10(7):662-9
pubmed: 26036609
Bioinformatics. 2007 Aug 1;23(15):1986-94
pubmed: 17599930
Nat Immunol. 2001 Mar;2(3):261-8
pubmed: 11224527
Nature. 2013 Dec 5;504(7478):138-42
pubmed: 24185007
Nucleic Acids Res. 2016 Jan 4;44(D1):D239-47
pubmed: 26590260
Genome Biol. 2013;14(10):R115
pubmed: 24138928
Nature. 2018 Aug;560(7718):325-330
pubmed: 30089904
Mol Cancer Ther. 2019 Dec;18(12):2421-2432
pubmed: 31527224
Cancer Immunol Res. 2017 Aug;5(8):618-629
pubmed: 28630054
Nat Med. 2020 May;26(5):781-791
pubmed: 32284588
Elife. 2015 Aug 12;4:
pubmed: 26267216
Nat Med. 2018 Oct;24(10):1545-1549
pubmed: 30127394

Auteurs

Miles C Andrews (MC)

Department of Medicine, Monash University, Melbourne, VIC, Australia.
Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Junna Oba (J)

Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Department of Extended Intelligence for Medicine, The Ishii-Ishibashi Laboratory, Keio University School of Medicine, Tokyo, Japan.

Chang-Jiun Wu (CJ)

Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Haifeng Zhu (H)

Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Tatiana Karpinets (T)

Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Caitlin A Creasy (CA)

Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Marie-Andrée Forget (MA)

Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Xiaoxing Yu (X)

Department of Extended Intelligence for Medicine, The Ishii-Ishibashi Laboratory, Keio University School of Medicine, Tokyo, Japan.

Xingzhi Song (X)

Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Xizeng Mao (X)

Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

A Gordon Robertson (AG)

Canada's Michael Smith Genome Sciences Center, BC Cancer, Vancouver, BC, Canada.
Dxige Research Inc., Courtenay, BC, Canada.

Gabriele Romano (G)

Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Peng Li (P)

Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Elizabeth M Burton (EM)

Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Yiling Lu (Y)

Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Robert Szczepaniak Sloane (RS)

Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Khalida M Wani (KM)

Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Kunal Rai (K)

Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Alexander J Lazar (AJ)

Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Lauren E Haydu (LE)

Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Matias A Bustos (MA)

Departments of Translational Molecular Medicine and Genomic Sequencing Center, St John's Cancer Institute, Providence Saint John's Health Center, Santa Monica, CA, USA.

Jianjun Shen (J)

Department of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Smithville, TX, USA.

Yueping Chen (Y)

Department of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Smithville, TX, USA.

Margaret B Morgan (MB)

Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Jennifer A Wargo (JA)

Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Lawrence N Kwong (LN)

Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Cara L Haymaker (CL)

Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Elizabeth A Grimm (EA)

Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Patrick Hwu (P)

Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
H Lee Moffitt Cancer Center, Tampa, FL, USA.

Dave S B Hoon (DSB)

Departments of Translational Molecular Medicine and Genomic Sequencing Center, St John's Cancer Institute, Providence Saint John's Health Center, Santa Monica, CA, USA.

Jianhua Zhang (J)

Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Jeffrey E Gershenwald (JE)

Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Michael A Davies (MA)

Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

P Andrew Futreal (PA)

Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Chantale Bernatchez (C)

Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Department of Biologics Development, Division of Therapeutics Discovery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Scott E Woodman (SE)

Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. swoodman@mdanderson.org.
Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. swoodman@mdanderson.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH